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OBJECTIVES We investigated the association of polymorphisms in the promoter region and exon 7
endothelial nitric oxide synthase (eNOS) gene with coronary artery disease (CAD).
BACKGROUND Endothelial dysfunction foretells cardiovascular events and can be genetically determined.
METHODS We genotyped for the promoter (T-786C) and exon 7 (Glu298Asp, G894T) polymorphisms
in 1,225 subjects; 1,106 were consecutive patients undergoing coronary angiography and 119
control subjects without any cardiovascular risk factors. Genotyping was performed with
melting curve analysis of polymerase chain reaction products from allele-specific acceptor and
donor probes that were 5- and 3-end labeled with LCRed640 and fluorescein, respectively;
CAD was assessed by quantitative coronary angiography. We performed multiple logistic
regression analysis for the effect of the T-786C, the missense Glu298Asp variant, and other
coronary risk factors on two- and three-vessel CAD.
RESULTS The overall genotype distribution of T-786C (CC  17.7%, CT  40.4%, and TT  41.9%)
and Glu298Asp (GG  43.3%, GT  37.0%, and TT  19.7%) was consistent with the
Hardy-Weinberg equilibrium. The regression analysis showed that the T-786C, but not the
missense Glu298Asp variant, significantly predicted CAD, independent of other risk factors.
Compared with TT homozygous, subjects carrying the C allele had a significant (p  0.002)
increase in the odds ratio of harboring two- or three-vessel CAD of 1.672 (95% confidence
interval, 1.062 to 2.527). A subgroup analysis confirmed this effect of the T-786C polymor-
phism in men (p  0.007), cigarette smokers (p  0.001), subjects older than 60 years of age
(p 0.007), with hypercholesterolemia (p 0.011), low high-density lipoprotein cholesterol
(p  0.006), and overweight or with obesity (p  0.041).
CONCLUSIONS The C allele at the T-786C endothelial nitric oxide synthase polymorphism is associated with
a higher risk of multivessel CAD in Caucasians. (J Am Coll Cardiol 2003;41:930–7)
© 2003 by the American College of Cardiology Foundation
Coronary artery disease (CAD), the leading cause of mor-
tality in Western countries (1), is a highly prevalent heter-
ogeneous disease that is genetically determined, albeit in a
complex fashion. Genetic mechanisms are deemed to in-
crease susceptibility to CAD and may account for a sub-
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stantial proportion of CAD variance, but, despite intensive
investigation, their identification has not been accomplished
thus far (2). This task proved to be unduly difficult for
several reasons, including the fact that the clinical identifi-
cation of the phenotype CAD can be inaccurate without
undertaking coronary angiography. The latter is invasive,
costly, inconvenient to the patients, and carries a small, but
not negligible, risk of complications (3); therefore, it was
not widely used in large studies. Instead, cardiovascular
(CV) events, including myocardial infarction (MI), and
sudden death, angina, need of coronary artery bypass surgery
and/or percutaneous transluminal coronary angioplasty, and
evidence for myocardial ischemia at noninvasive tests, were
used as surrogates of CAD based on the assumption that
they could mirror the presence of CAD. These crude
phenotype definitions might well account for the negative or
conflicting results that were accomplished.
An impaired endothelium-dependent vasodilation (4) has
been consistently reported in conditions that are associated
with accelerated atherosclerosis, such as arterial hyperten-
sion, cigarette smoking, diabetes mellitus, hypercholesterol-
emia, hyperhomocyst(e)inemia, and aging (5,6). Further-
more, a blunted endothelium-dependent vasodilation was
found to predict CV events independently of the common
risk factors (7) and, therefore, might be a precursor of CAD.
Nitric oxide (NO) is a major mediator of endothelium-
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dependent vasodilation made in endothelial cells from
L-arginine through the action of the homodimeric enzyme
endothelial nitric oxide synthase (eNOS). In addition to its
key role in the regulation of vascular tone and blood pressure
(8,9), NO is thought to be involved in atherogenesis
(8,10,11), development of heart failure, and congenital
septal defects and vascular remodeling, as shown by data in
mice lacking the eNOS gene (10,12). In fact, NO blunts the
activity of the nuclear factor-kappaB family of transcription
factors (13,14) and, thereby, can prevent the endothelial
expression of adhesion molecules and inflammatory cyto-
kines, which are instrumental for the triggering of athero-
genesis (15). Accordingly, a genetically determined im-
paired availability of NO might be a major risk factor for
development of CAD.
The eNOS gene (16) is expressionally and functionally
regulated through multiple regulatory steps (14,17) and
entails several polymorphisms (18), some of which bear
functional consequences. Therefore, this gene is a likely
candidate for impaired endothelium-dependent vasodilation
and CAD. Some eNOS gene polymorphisms have indeed
been linked to CV phenotypes and events (19–28), and two
of them to coronary spasm (23,29). Of the latter, the T-786C
is located in the promoter region, which is the most
important for the regulation of the transcription rate of the
eNOS gene (29). The mutant C allele implies a blunted
transcription rate and was found to be far more common in
Japanese patients with vasospastic angina than in controls
(29); furthermore, we recently reported that this allele was
associated with a blunted forearm vasodilation in response
to acetylcholine in hypertensive patients (30).
Another eNOS polymorphism, the GAG to GAT sub-
stitution in exon 7, results in the replacement of glutamate
by aspartate (Glu298Asp, G894T), which might impair the
function of eNOS by causing a tight turn of the alpha-helix
(23), as suggested by some studies (31–34).
As both polymorphisms were found to be associated with
an altered coronary vasomotor reactivity and with an im-
paired endothelium-dependent vasodilation (29,30), we hy-
pothesized that they might play a role for the triggering of
atherogenesis and CAD occurrence. However, only limited
and conflicting results were available so far to support this
hypothesis. No association of the T-786C polymorphism
with CV events (35) and of the Glu298Asp polymorphism
with MI was seen in Caucasians (36). However, both these
studies relied on CV events and not on coronary angiogra-
phy for the assessment of CAD.
Thus, within the Genetic and ENvironmental factors In
Coronary Atherosclerosis (GENICA) study, a large pro-
spective investigation of the genetic determinants of CAD,
which was performed in consecutive Caucasian patients
undergoing coronary angiography, we sought to determine
if the T-786C and the Glu298Asp polymorphisms predicted
multivessel CAD.
METHODS
The criteria for enrollment of the patients and controls in
the GENICA study were previously reported (37). In brief,
consecutive Caucasian patients of both genders consecu-
tively referred to the Division of Cardiology of the Citta-
della General Hospital for coronary angiography for inves-
tigation of chest pain and/or suspected CAD were enrolled
between 1999 and 2001. The Medical Ethics Committee of
our university approved the study protocol, and a written
consent after explanation of the aims and details of the study
was obtained from each participant. The refusal to partici-
pate in this study was the only exclusion criterion. Two
groups served as controls: group 1 entailed patients in whom
significant (e.g., stenosis 50%) CAD was eventually ruled
out by coronary angiography; group 2 comprised 119
consecutive healthy normotensive blood donors enrolled at
the local blood bank during the same period. In these latter
subjects, it was unethical to perform coronary angiography
to rule out the presence of asymptomatic CAD. Therefore,
the following inclusion criteria were used: negative family
history of CAD, MI, and stroke; nonsmoking status;
absence of hypercholesterolemia, hypertriglyceridemia, dia-
betes mellitus, all defined as specified in the following text.
Based on available data from epidemiologic and family
studies, a cohort fulfilling these criteria is expected to have
a very low prevalence of asymptomatic CAD.
Demographic and clinical measurements. A standard
questionnaire was used to carefully ascertain medical history
in all participants (transient ischemic attack, stroke, angina,
MI, coronary artery bypass, percutaneous transluminal cor-
onary angioplasty, renal failure, peripheral artery disease,
and history of vascular surgical interventions), smoking
habits, presence/absence of hypertension, diabetes, hyper-
cholesterolemia, hypertriglyceridemia, and current medica-
tions. Body mass index was calculated as weight/height2
(kg/m2). Patients were classified into three groups: current
smokers, nonsmokers, and ex-smokers (who had stopped
smoking for at least one year). Diabetes mellitus (type I or
II) was defined as a previous diagnosis of the disease, history
of antidiabetic medications, or plasma fasting levels of
glucose 126 mg/dl (7.0 mmol/l) on at least two occasions.
Impaired glucose tolerance was defined as plasma fasting
levels of glucose ranging between 110 to 126 mg/dl (6.1 to
6.9 mmol/l) (38). Hypercholesterolemia was defined as a
Abbreviations and Acronyms
CAD  coronary artery disease
CV  cardiovascular
eNOS  endothelial nitric oxide synthase
GENICA  Genetic and ENvironmental Factors in
Coronary Atherosclerosis study
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LDL  low-density lipoprotein
MI  myocardial infarction
NO  nitric oxide
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low-density lipoprotein (LDL) cholesterol 100 mg/dl
according to the National Cholesterol Education Program
guidelines for patients with CAD (39); hypertriglyceridemia
was defined as plasma fasting levels 134 mg/dl, that is,
higher than the 95th percentile value of our group 1 control
subjects. Blood pressure was measured by mercury sphyg-
momanometer using Korotkoff phase V for diastolic, ac-
cording to the World Health Organization guidelines.
Hypertension was defined as systolic pressure 140 mm
Hg, and/or diastolic pressure 90 mm Hg (40), or use of
any antihypertensive agents.
Coronary angiography. Angiography was carried out and
evaluated by experienced cardiologists who were blinded to
patients’ genotype. The severity of CAD was determined by
the number of significantly stenosed coronary arteries (41).
Patients were classified as follows: code 1  normal vessels;
code 250% stenosis; code 3, 4, and 5 stenosis 50%
in one, two, or three major coronary arteries, respectively.
Laboratory measurements. Each patient was studied be-
tween 8:30 and 12:00 A.M. Before coronary angiography,
blood samples were taken from the femoral artery and were
immediately put on ice and centrifuged at 3,000 g (at 4°C
for 10 min). Total cholesterol, high-density lipoprotein
(HDL) cholesterol, triglycerides, glycemia, sodium, potas-
sium, blood urea nitrogen, and creatinine levels were mea-
sured with conventional methods.
Extraction of deoxyribonucleic acid and eNOS genotyp-
ing. The blood was stored at 20°C until deoxyribonucleic
acid was extracted using a commercially available kit (DNA
Blood Extraction Fast KIT, Analitica Srl., Padova, Italy).
Details of the methodology used for genotyping at each
polymorphism, including oligonucleotides serving as ampli-
fication primers and fluorescence resonance energy transfer
probes, were recently reported (30).
Statistical analysis. One-way analysis of variance followed
by Bonferroni’s post-hoc test was used to compare quanti-
tative variables between CAD patients and control subjects.
Chi-squared analysis was used to compare the frequencies of
the categorical coronary risk factors and of eNOS gene
variants between the CAD and the control groups. Consis-
tency of the genotype frequencies with the Hardy-Weinberg
equilibrium was also tested by chi-squared analysis. To
identify the independent risk factors for CAD, we per-
formed multiple logistic regression analysis for the effect of
the T-786C, the missense Glu298Asp variant, and the other
coronary risk factors. To this end, independent variables
were coded as dummy variables as follows: age, 0 for 60
years, 1 for60 years; gender, 0 for female, 1 for male; body
mass index, 0 for 26 kg/m2, 1 for 26 kg/m2; hyperten-
sion, diabetes mellitus, and LDL cholesterol, 100 mg/dl,
0 for absence, 1 for presence; cigarette smoking, 0 for
nonsmoker, 1 for current or ex-smoker; the T-786C, 0 for
CC, 1 for CT, and 2 for TT; missense Glu298Asp variant,
0 for GG, 1 for TG, and 2 for TT (42). Because the aim of
this study was to identify predictors of multivessel CAD,
the dependent variable was coded as follows: 0 for normal
coronary artery and for stenosis 50%; 1 for stenosis 50%
in two or three major epicardial vessels. The forward
stepwise selection (Wald criterion) was used. Odds ratios
(approximating to relative risks) were calculated as a mea-
sure of the association between the eNOS genotype and the
CAD phenotype, with the effect of the mutant allele C for
the T-786C polymorphism assumed to be dominant (TT vs.
CT and CC) or additive (TT and CT combined vs. CC).
Similarly, for the Glu298Asp polymorphism, the effect of
the mutant allele was investigated according to a dominant
(TT and TG combined vs. GG) or additive (TT vs. GT and
GG) model of inheritance. For each odds ratio, we calcu-
lated two-tailed p values and 95% confidence intervals.
Statistical significance was defined as p  0.05. All analyses
were performed using SPSS 10.0 for Windows (SPSS Italy
Inc., Bologna, Italy).
RESULTS
Demographic characteristics and eNOS genotype distri-
bution. Of the 1,271 patients originally recruited in the
GENICA study who had complete coronary angiography
data, 17% (n  217) were found to have normal coronary
arteries, and 14% (n 178) stenosis50%, 23% (n 290),
24% (n  305), and 22% (n  281) had significant (50%)
stenosis in one, two, or three major epicardial vessels,
respectively. The eNOS polymorphism genotypes were
available in 1,106 (87%) of all patients. A preliminary
regression analysis on all subjects revealed a borderline
significant (p  0.034) association between the T-786C
eNOS genotype and one-, two-, or three-vessel CAD.
Therefore, to maximize contrast at the phenotype level, it
was decided to combine two- and three-vessel CAD pa-
tients, as CAD group, and normal vessel and50% stenosis
as control group (group 1); thus, the CAD group and group
1 comprised 749 and 330 patients, respectively. Of the
latter, 21% were healthy individuals, 39% had valvular heart
disease, 15% had cardiomyopathy (13.7% dilated, 1.3%
hypertrophic), 7% had hypertensive heart disease, and 18%
had ischemic cardiomyopathy. The latter diagnosis was
based on resting and stress electrocardiogram and on results
of stress myocardial scintigraphy that showed inducible
ischemia.
The demographic and clinical characteristics of the CAD
patients and of group 1 and 2 (119 subjects) controls are
shown in Table 1. The CAD patients were older, had
higher plasma glucose and triglycerides, and lower HDL
cholesterol than control subjects. There were more males in
CAD patients than in group 1 (p  0.001), but not group
2 control subjects. Compared with both control groups,
more CAD patients had diabetes mellitus, hypercholester-
olemia (both p  0.001), hypertriglyceridemia (p  0.001),
and were smokers or ex-smokers (p  0.0001). Compared
with controls, the CAD patients more commonly reported
a history of myocardial infarction (p  0.0001), coronary
artery bypass surgery (p  0.0001), percutaneous translu-
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minal coronary angioplasty (p  0.0001), peripheral artery
disease (p 0.001), vascular surgery (p 0.001), but not of
transient ischemic attack or stroke.
Screening for the T-786C polymorphism and the missense
Glu298Asp variant of the eNOS gene. The overall geno-
type distribution of the T-786C polymorphism was CC 
17.7%, CT  40.4%, and TT  41.9%; the C and T allele
frequency was 0.38 and 0.62, respectively. For the
Glu298Asp polymorphism, the genotype distribution was
GG  43.3%, GT  37.0%, and TT  19.7; the G and T
allele frequency was 0.62 and 0.38, respectively. The distri-
bution of both polymorphisms agreed with the Hardy-
Weinberg equilibrium; it did not differ between CAD and
control patients for the T-786C polymorphism. The fre-
quency of the Glu298Asp genotypes did not differ between
CAD patients and group 1 controls, whereas, in group 2,
there was a slight excess of GG homozygous (p  0.015).
For both polymorphisms, all demographic and clinical
variables did not differ between genotypes.
We investigated whether there was a linkage between the
T-786C and the Glu298Asp polymorphism, by Kendall’s tau
b and Spearman’s correlation analysis, and found a highly
significant (p  0.001) relationship between the two poly-
morphisms (Kendall’s tau b  0.303  0.025; Spearman’s
correlation  0.330  0.027).
Association between T-786C, Glu298Asp, eNOS vari-
ants, and CAD. We found with the logistic regression
analysis that the T-786C polymorphism significantly pre-
dicted CAD. In Table 2 we ranked the variables that
entered into the model according to the value of the Wald
coefficient, which estimates the usefulness of the parameter
to the model. Besides confirming that male gender, age,
hypertriglyceridemia, and cigarette smoking were significant
predictors of CAD, we found that the C allele also signif-
icantly predicted CAD, being as useful as cigarette smoking
to this end. At variance, other “classical” CV risk factors,
such as arterial hypertension, diabetes mellitus, obesity, and
elevated LDL cholesterol, did not remain in the model and,
therefore, were less useful than the C allele as predictors of
CAD. Subjects carrying the C allele, either homozygous or
heterozygous, had a 69.2% increased risk of having signif-
icant multivessel CAD. We observed similar results when
the C allele was examined according to an additive model,
that is, CC homozygous versus CT and TT (Table 2). In
contrast, no effect of the Glu298Asp missense variant on
CAD was detected. The association of the C allele with
multivessel CAD was even stronger (p  0.001) when the
18% of group 1 control patients with ischemic cardiomyop-
athy were excluded from the analysis.
Subgroup analysis (Fig. 1) confirmed the association of
Table 1. Clinical Characteristics of the CAD Patients and the Control Subjects
Group Variables
CAD
(n  749)
p vs.
Group 1
Controls
Group 1
(n  330)
p vs.
Group 2
Group 2
(n  119)
p vs.
CAD
Age, yrs 64.3  9.4 0.001 62.0  10.8  0.001 32.8  8.0  0.001
Gender M/F (%) 611 (82%)/138 (18%)  0.001 191 (58%)/139 (42%)  0.001 103 (87%)/16 (13%) NS
BMI (kg/m2) 26.9  3.8 NS 26.8  4.4  0.001 23.9  3.6  0.001
Systolic BP (mm Hg) 135  18 NS 134  17  0.001 119  8  0.001
Diastolic BP (mm Hg) 78  10 NS 79  10  0.001 70  7  0.001
Mean BP (mm Hg) 97  11 NS 97  11  0.001 86  7  0.001
Heart rate (beats/min) 66  10 NS 69  10 NS NA NS
Total cholesterol (mg/dl) 206  44 NS 202  41  0.001 175  22  0.001
HDL cholesterol (mg/dl) 45  11  0.001 48  13 – NA –
LDL cholesterol (mg/dl) 131  36 NS 129  34 – NA –
Triglycerides (mg/dl) 147  98  0.001 125  71  0.001 73  35  0.001
Glycemia (mg/dl) 115  40  0.001 108  25  0.001 88  8  0.001
Left ventricular ejection fraction (%) 60  14 NS 60  16 – NA –
Diabetes mellitus (%) 19.0 0.004 11.5  0.001 0  0.001
Nonsmoker/smokers/ex-smokers (%) 35.0/14.2/50.8  0.001 59.1/14.3/26.5  0.001 100/0/0  0.001
Hypertensives (%) 61.4 NS 56.6  0.001 0  0.001
Hypercholesterolemia (%) 59.4  0.001 46.1  0.001 0  0.001
Hypertriglyceridemia (%) 22.7  0.001 13.3  0.001 0  0.001
Cholesterol-lowering drugs (%) 38.6  0.001 18.8  0.001 0  0.001
History of
Transient ischemic attack (%) 3.5 NS 4.6 0.009 0 0.026
Ischemic stroke (%) 1.7 NS 1.2 NS 0 NS
Acute myocardial infarction (%) 45.6  0.001 11.7  0.001 0  0.001
Coronary artery bypass surgery (%) 12.1  0.001 0 NS 0  0.001
Percutaneous coronary angioplasty (%) 9.3  0.001 0.3 NS 0  0.001
Peripheral arterial disease (%) 17.5 0.008 11.7  0.001 0  0.001
Vascular surgery (%) 5.4 0.036 2.2 0.051 0 0.002
Chronic renal failure (%) 6.7 0.042 3.7 0.027 0  0.001
Results are expressed as mean  SD.
BMI  body mass index; BP  blood pressure; CAD  coronary artery disease; HDL  high-density lipoprotein; LDL  low-density lipoprotein; NA  not available.
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the C allele with CAD also when men (p 0.007), subjects
older than 60 years of age (p  0.007), subjects with
hypercholesterolemia (p  0.011), cigarette smokers (p 
0.001), subjects with low HDL cholesterol (p 0.006), and
overweight or with obesity (p  0.041) were considered.
When subjects with at least four such unfavorable features
were considered, the odds ratio associated with the C allele
further increased the relative risk (odds ratio  3.61; 95%
confidence interval, 1.63 to 8; p  0.002) of having
significant multivessel CAD.
DISCUSSION
This study showed a significant association between severe
CAD and the T-786C polymorphism, located in the eNOS
gene promoter, independently of the most common CV risk
factors. At variance, we could find no evidence for such
association with the Glu298Asp polymorphism in exon 7.
Thus, our results identified a genetic determinant of CAD
in Caucasian individuals.
Reporter gene studies showed that the T-786C substitu-
tion in the promoter region of eNOS reduced by 50% the
rate of transcription of eNOS, both under baseline condi-
tions and in response to hypoxia (29), and was associated
with decreased serum levels of nitrite/nitrate (43). These
effects might depend upon the fact that a mutant allele can
bind the replication protein A1, which acts as a gene
repressor protein (43). The mutant C allele was found to be
quite rare in healthy Japanese subjects (3%) and more
common (15%) in patients with coronary spasm, thus
indicating a highly significant (p 0.0001) association with
an altered coronary vasomotor responses in this ethnic
group (44). We found the C allele in 38% of our cohort,
which is consistent with the 37.8% recently reported in
British middle-age men from primary care practices (35).
Thus, this allele seems to be much more common in
Caucasian than in Japanese individuals, albeit the underly-
ing reasons remain hypothetical.
To our knowledge there was no data supporting the
relevance of the T-786C polymorphism in non-Japanese
populations, because no association with CAD was found in
one study (35). Our results filled this gap by showing that
the C allele was associated with CAD in Caucasian subjects.
The logistic regression (Table 2) showed that subjects who
carried the C allele exhibited a 73% increase of the risk of
harboring significant multivessel coronary artery narrowing.
This significant association does not imply, per se, a causal
relationship; neither does it clarify the basic mechanisms.
However, it is worth pointing out that, in a large series of
mild-to-moderate uncomplicated essential hypertensive pa-
tients who underwent an infusion of the endothelium-
dependent vasodilator acetylcholine into the brachial artery,
the TT homozygous subjects exhibited a significantly en-
hanced vasodilation, as compared with CT and CC indi-
viduals (30). Thus, it would appear that, in a condition that
implies enhanced oxidative stress, such as arterial hyperten-
sion, the genetic predisposition to generate less NO can
become apparent and, in the long run, might be detrimental
and result in susceptibility to atherogenesis.
This contention is further supported by the present
subgroup analysis. We found that the concomitance of at
least one major CV risk factor further enhanced the addi-
tional risk associated with the C allele and that the concur-
rence of multiple risk factors markedly enhanced the nefar-
ious effects of the C allele (Fig. 1). Thus, under most
conditions that imply oxidative stress, such as aging, smok-
ing, hypercholesterolemia, male gender (lack of estrogens),
and overweight or obesity, the genetic predisposition to
generate less NO associated with the C allele could con-
tribute to decreasing the bioavailability of NO and, thus, to
the triggering of coronary atherogenesis.
Recent studies showed an association of the T (mutant)
allele at the Glu298Asp polymorphism with human pheno-
types that can be relevant for CV disease, including vascular
adaptation to pregnancy (34), endothelial response to smok-
ing and n-3 fatty acids (32), high-altitude pulmonary edema
(33), and a lower mean age at end-stage renal disease in
patients with autosomal dominant polycystic kidney disease
(31). We found that frequency of the T (mutant) allele was
38%, that is, much higher than in Japanese (6.7% to 10.7%
in a study [42], 9.8% to 25.6% in another study [33]), but
similar to that observed in Caucasians from continental
Europe (31% to 34%) (31,45), albeit lower than in U.K.
patients (68.8% and 52.2% in control subjects and CAD
patients, respectively) (36). We found no evidence for an
association of this polymorphism with severity of CAD in
agreement with earlier and more recent studies
(26,35,42,45,46) but in contrast to reports of an association
of the Glu298 with MI (36,42). This might not be surpris-
Table 2. Results of Logistic Multivariate Analysis for T-786C
Variables in the Model B SE Wald p Value OR (95% CI)
Gender 1.201 0.210 32.78  0.0001 0.301 (0.199–0.454)
Age 0.654 0.179 13.396  0.0001 0.520 (0.366–0.738)
Hypertriglyceridemia 0.559 0.176 10.122 0.001 0.572 (0.405–0.807)
T-786 variant (C dominant) 0.546 0.172 10.112 0.001 1.727 (1.233–2.419)
Cigarette smoking 0.546 0.186 8.635 0.003 0.579 (0.402–0.834)
Diabetes mellitus 0.551 0.206 7.154 0.007 0.576 (0.385–0.863)
T-786 variant (C additive) 0.521 0.211 6.094 0.014 1.684 (1.113–2.546)
The following variables did not enter into the model: arterial hypertension, low-density lipoprotein cholesterol  100 mg/dl,
Glu298Asp polymorphism (both dominant and codominant).
B  estimated coefficient; CI  confidence interval; OR  odds ratio; SE  standard error.
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Figure 1. Results of the logistic regression analysis in the different risk subgroups of subjects and in subjects with concurrence of at least four major risk
factors (top). The squares (closed for the T-786C C allele; open for the other variables) and the lines indicate, respectively, the value of the B coefficient
(an estimate of the odds ratio) and its 95% confidence interval. For the purpose of visual clarity, the reciprocal value of the B coefficient that was 1 was
used. The figure shows the independent variables that remained in the model, that is, were significant predictors of multivessel coronary artery disease
(CAD) in each subgroup, ranked from bottom to top according to the value of the Wald coefficient. Notice the usefulness of T-786C polymorphism for
the prediction of multivessel CAD in all subgroups. The coexistence of four major risk factors (subgroup at the top) resulted in a clear-cut increase of the
odds ratio for C allele of the T-786C polymorphism, further confirming the usefulness of this endothelial nitric oxide synthase molecular variant for the
prediction of multivessel CAD. HDL  high-density lipoprotein; LDL  low-density lipoprotein.
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ing because: 1) the replacement of aspartate for glutamate is
deemed to be a conservative one, and 2) recombinant eNOS
Asp298 and Glu298 enzymes showed no discernible differ-
ence in the Michaelis constant (Km) or the maximum
velocity (Vmax) (18). However, at variance with this latter
finding, it was found that the enzymatic activity of eNOS
was systematically decreased in renal artery specimens of
patients harboring the T allele (31). Thus, either the
functional impact of this polymorphism can differ between
the renal and the coronary artery bed or this polymorphism
could only act as a marker for a functional locus elsewhere in
the gene, as suggested by the observation of a linkage
disequilibrium with other eNOS polymorphisms (35). Of
much interest, we found evidence of a significant linkage
between T-786C and the Glu298Asp polymorphism, at
variance with a previous report (47). Thus, available con-
flicting results on the association of the Glu298Asp poly-
morphism with CAD or CV events might be explained on
the basis of a variable association of this variant with the
T-786C polymorphism in different populations. However,
individuals carrying the T allele (TT and TG) were found to
have significantly higher pressor responses to phenylephrine
than GG homozygous, thus suggesting that the T allele
might increase vascular reactivity (48), possibly because the
Asp298, but not the Glu298, variant of eNOS is susceptible
to cleavage (49). Whatever the functional relevance of the
missense Glu298Asp variant might be, our results in indi-
viduals from southern Europe, consistent with earlier stud-
ies (26,35,42), do not support the contention that
Glu298Asp polymorphism is, per se, strongly associated
with CAD in Caucasian patients.
This cross-sectional study comprised exclusively Cauca-
sians, and, therefore, our findings might not apply to other
ethnic groups or indicate a prognostic value of the T-786C
polymorphism, which might be revealed by an ongoing
follow-up study. Furthermore, only a minority of our study
population was women, while estrogens are known to
enhance NO availability and to account for protection of
fertile women from CV events. We could confirm the
usefulness of the T-786C polymorphism as a predictor of
CAD in men but not in women; however, we cannot
exclude the possibility that this study was underpowered to
detect an association of the T-786C eNOS polymorphism
with CAD in both genders.
In conclusion, we have found that a functional polymor-
phism of the eNOS gene, the T-786C, which is located in
the promoter region, was significantly associated with severe
CAD, independent of the other common CV risk factors in
Caucasian patients.
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